ImmunityBio (NASDAQ:IBRX – Get Free Report) and ADMA Biologics (NASDAQ:ADMA – Get Free Report) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.
Analyst Ratings
This is a breakdown of recent ratings and target prices for ImmunityBio and ADMA Biologics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ImmunityBio | 0 | 1 | 0 | 0 | 2.00 |
| ADMA Biologics | 0 | 0 | 3 | 1 | 3.25 |
ImmunityBio presently has a consensus price target of $6.00, suggesting a potential downside of 13.54%. ADMA Biologics has a consensus price target of $10.50, suggesting a potential upside of 9.03%. Given ADMA Biologics’ stronger consensus rating and higher probable upside, analysts plainly believe ADMA Biologics is more favorable than ImmunityBio.
Volatility & Risk
Profitability
This table compares ImmunityBio and ADMA Biologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ImmunityBio | -198,994.05% | N/A | -114.89% |
| ADMA Biologics | -1.29% | 17.24% | 7.38% |
Valuation & Earnings
This table compares ImmunityBio and ADMA Biologics’ revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ImmunityBio | $620,000.00 | 7,741.12 | -$583.20 million | ($1.09) | -6.37 |
| ADMA Biologics | $258.21 million | 8.51 | -$28.24 million | ($0.02) | -481.50 |
ADMA Biologics has higher revenue and earnings than ImmunityBio. ADMA Biologics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 83.4% of ImmunityBio shares are held by insiders. Comparatively, 3.7% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
ADMA Biologics beats ImmunityBio on 11 of the 15 factors compared between the two stocks.
About ImmunityBio
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies. Its lead biologic commercial product candidate is Anktiva, an IL-15 superagonist antibody-cytokine fusion protein for the treatment of bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease. The company also develops other therapeutic agents for the treatment of liquid and solid tumors, including bladder, lung, colorectal, and ovarian cancers, as well as glioblastoma multiforme, acute myeloid leukemia, and human immunodeficiency virus. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., and Viracta Therapeutics, Inc. The company is based in San Diego, California.
About ADMA Biologics
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.
